JP2008524210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524210A5 JP2008524210A5 JP2007546609A JP2007546609A JP2008524210A5 JP 2008524210 A5 JP2008524210 A5 JP 2008524210A5 JP 2007546609 A JP2007546609 A JP 2007546609A JP 2007546609 A JP2007546609 A JP 2007546609A JP 2008524210 A5 JP2008524210 A5 JP 2008524210A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- pharmaceutically acceptable
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- AOSSJKMXLBALBV-JOCHJYFZSA-N (5s)-5-[[6-(2-cyclobutylpyrimidin-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=NC=3)C3CCC3)=CC=C2CN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O AOSSJKMXLBALBV-JOCHJYFZSA-N 0.000 claims 1
- KFSHRBYTUSBDGT-OAQYLSRUSA-N (5s)-5-[[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-1h-2,7-naphthyridin-2-yl]sulfonylmethyl]-5-ethylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=NC=3)C3CC3)=NC=C2CN1S(=O)(=O)C[C@@]1(CC)NC(=O)NC1=O KFSHRBYTUSBDGT-OAQYLSRUSA-N 0.000 claims 1
- LDPJXGRNICHPCB-HXUWFJFHSA-N (5s)-5-[[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-1h-2,7-naphthyridin-2-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=NC=3)C3CC3)=NC=C2CN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O LDPJXGRNICHPCB-HXUWFJFHSA-N 0.000 claims 1
- GNPKJIOJLOETEO-JOCHJYFZSA-N (5s)-5-[[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]sulfonylmethyl]-5-ethylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=NC=3)C3CC3)=CC=C2CN1S(=O)(=O)C[C@@]1(CC)NC(=O)NC1=O GNPKJIOJLOETEO-JOCHJYFZSA-N 0.000 claims 1
- OEQLCXYTKIRISP-OAQYLSRUSA-N (5s)-5-[[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=NC=3)C3CC3)=CC=C2CN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O OEQLCXYTKIRISP-OAQYLSRUSA-N 0.000 claims 1
- BMXGUKRYJMVPCE-OAQYLSRUSA-N (5s)-5-[[6-(6-cyclopropylpyridin-3-yl)-3,4-dihydro-1h-2,7-naphthyridin-2-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione Chemical compound C1CC2=CC(C=3C=NC(=CC=3)C3CC3)=NC=C2CN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O BMXGUKRYJMVPCE-OAQYLSRUSA-N 0.000 claims 1
- LPMNKIDUXUPDBL-QHCPKHFHSA-N (5s)-5-cyclopropyl-5-[[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydro-1h-isoquinolin-2-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound N1C(=O)NC(=O)[C@@]1(C1CC1)CS(=O)(=O)N1CC2=CC=C(C=3C=NC(=NC=3)C3CC3)C=C2CC1 LPMNKIDUXUPDBL-QHCPKHFHSA-N 0.000 claims 1
- BIUIDDFOHIEILW-JOCHJYFZSA-N (5s)-5-methyl-5-[[6-[2-(1-methylcyclopropyl)pyrimidin-5-yl]-3,4-dihydro-1h-isoquinolin-2-yl]sulfonylmethyl]imidazolidine-2,4-dione Chemical compound N=1C=C(C=2C=C3CCN(CC3=CC=2)S(=O)(=O)C[C@]2(C)C(NC(=O)N2)=O)C=NC=1C1(C)CC1 BIUIDDFOHIEILW-JOCHJYFZSA-N 0.000 claims 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 235000012501 ammonium carbonate Nutrition 0.000 claims 1
- 239000001099 ammonium carbonate Substances 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 0 *C(CS(I)(=O)=O)(C(N1)=O)NC1=O Chemical compound *C(CS(I)(=O)=O)(C(N1)=O)NC1=O 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0403085A SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Novel componds |
| PCT/SE2005/001917 WO2006065215A1 (en) | 2004-12-17 | 2005-12-14 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524210A JP2008524210A (ja) | 2008-07-10 |
| JP2008524210A5 true JP2008524210A5 (https=) | 2009-01-29 |
Family
ID=34075235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546609A Pending JP2008524210A (ja) | 2004-12-17 | 2005-12-14 | メタロプロテイナーゼ阻害剤としての新規ヒダントイン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7655664B2 (https=) |
| EP (1) | EP1831199B1 (https=) |
| JP (1) | JP2008524210A (https=) |
| KR (1) | KR20070090924A (https=) |
| CN (1) | CN101119987A (https=) |
| AR (1) | AR051795A1 (https=) |
| AT (1) | ATE545642T1 (https=) |
| AU (1) | AU2005317286B2 (https=) |
| BR (1) | BRPI0517035A (https=) |
| CA (1) | CA2590845A1 (https=) |
| ES (1) | ES2380670T3 (https=) |
| IL (1) | IL183599A (https=) |
| MX (1) | MX2007007023A (https=) |
| MY (1) | MY147770A (https=) |
| NO (1) | NO20073572L (https=) |
| NZ (1) | NZ555831A (https=) |
| RU (1) | RU2376301C2 (https=) |
| SA (1) | SA05260409B1 (https=) |
| SE (1) | SE0403085D0 (https=) |
| TW (1) | TW200635917A (https=) |
| UA (1) | UA90285C2 (https=) |
| WO (1) | WO2006065215A1 (https=) |
| ZA (1) | ZA200705075B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| EP1859356B1 (en) * | 2005-03-16 | 2019-07-10 | Sensus Metering Systems Inc. | Method, system, apparatus, and computer program product for determining a physical location of a sensor |
| MX2007013595A (es) * | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| TW200740769A (en) * | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| KR101271219B1 (ko) * | 2011-01-27 | 2013-06-07 | 광주과학기술원 | 신규한 하이단토인 유도체 및 이의 용도 |
| JP6258508B2 (ja) * | 2013-12-31 | 2018-01-10 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | 新規のイミダゾリジン−２，４−ジオン誘導体 |
| US20200268728A1 (en) | 2016-12-20 | 2020-08-27 | Sumitomo Dainippon Pharma Co., Ltd. | Drug targeting cancer stem cell |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| MX2024008003A (es) | 2021-12-28 | 2024-07-12 | Nippon Shinyaku Co Ltd | Compuesto de indazol y composicion farmaceutica. |
| CA3258111A1 (en) * | 2022-05-30 | 2025-04-07 | Scinnohub Pharmaceutical Co., Ltd | USE OF A TETRAHYDRONAPHTYRIDINE DERIVATIVE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO ADHESION |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2327890A (en) * | 1940-04-17 | 1943-08-24 | Parke Davis & Co | Substituted phenoxyalkyl ethers |
| US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
| US3452040A (en) * | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
| US3529019A (en) | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
| US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
| US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
| GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| US4529019A (en) * | 1981-07-28 | 1985-07-16 | The Crowell Corporation | Safe tire inflator |
| JPS6172762A (ja) | 1984-09-17 | 1986-04-14 | Kanegafuchi Chem Ind Co Ltd | 光学活性ヒダントイン類の製造法 |
| JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | Ｄ−α−アミノ酸の製造方法 |
| CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
| GB8618559D0 (en) | 1986-07-30 | 1986-09-10 | Genetics Int Inc | Rhodococcus bacterium |
| JPH0279879A (ja) | 1988-09-17 | 1990-03-20 | Canon Inc | 画像形成装置 |
| US4983771A (en) * | 1989-09-18 | 1991-01-08 | Hexcel Corporation | Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid |
| NL9000386A (nl) | 1990-02-16 | 1991-09-16 | Stamicarbon | Werkwijze voor de bereiding van optisch aktief aminozuuramide. |
| DK161690D0 (da) | 1990-07-05 | 1990-07-05 | Novo Nordisk As | Fremgangsmaade til fremstilling af enantiomere forbindelser |
| IL99957A0 (en) | 1990-11-13 | 1992-08-18 | Merck & Co Inc | Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them |
| PH31245A (en) | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| NL9201230A (nl) | 1992-07-09 | 1994-02-01 | Dsm Nv | Werkwijze voor de bereiding van optisch aktief methionineamide. |
| EP0640594A1 (en) | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Hydantoin derivative as metalloprotease inhibitor |
| WO1995014025A1 (en) | 1993-11-16 | 1995-05-26 | Merck & Co., Inc. | Piperidinylcamphorsulfonyl oxytocin antagonists |
| DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
| ZA96211B (en) | 1995-01-12 | 1996-07-26 | Teva Pharma | Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| IL123431A (en) * | 1995-11-22 | 2001-05-20 | Darwin Discovery Ltd | Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF) |
| GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
| US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| WO1998017645A1 (en) * | 1996-10-22 | 1998-04-30 | Pharmacia & Upjohn Company | α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS |
| WO1998050359A1 (en) | 1997-05-06 | 1998-11-12 | Novo Nordisk A/S | Novel heterocyclic compounds |
| PT877019E (pt) * | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| PL337854A1 (en) | 1997-07-31 | 2000-09-11 | Abbott Lab | Inverse hydroxamines as inhibitors of intercellular substance metaloproteinases |
| TW514634B (en) | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
| BR9814147A (pt) | 1997-11-12 | 2000-10-03 | Darwin Discovery Ltd | "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf" |
| JP4750272B2 (ja) | 1998-02-04 | 2011-08-17 | ノバルティス アーゲー | マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体 |
| US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| AU4074799A (en) * | 1998-05-14 | 1999-11-29 | Du Pont Pharmaceuticals Company | Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| IL140040A0 (en) | 1998-06-03 | 2002-02-10 | Guilford Pharm Inc | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| CA2333554A1 (en) * | 1998-06-17 | 1999-12-23 | Chu-Baio Xue | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
| US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| US6479502B1 (en) | 1998-08-29 | 2002-11-12 | British Biotech Pharmaceuticals | Hydroxamic acid derivatives as proteinase inhibitors |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| DE69907238T2 (de) | 1998-10-07 | 2003-11-06 | Yazaki Corp., Tokio/Tokyo | Sol-gel verfahren unter verwendung poröser formen |
| EP1004578B1 (en) * | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| HUP0104987A3 (en) | 1998-12-18 | 2002-09-30 | Axys Pharmaceuticals Inc South | Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them |
| AU1817700A (en) | 1998-12-31 | 2000-07-24 | Aventis Pharmaceuticals Inc. | 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12 |
| US6340691B1 (en) * | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| CN1343219A (zh) | 1999-01-28 | 2002-04-03 | 中外制药株式会社 | 取代的苯乙基胺衍生物 |
| US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
| GB9916562D0 (en) | 1999-07-14 | 1999-09-15 | Pharmacia & Upjohn Spa | 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora |
| US20020006920A1 (en) * | 1999-07-22 | 2002-01-17 | Robinson Ralph Pelton | Arylsulfonylamino hydroxamic acid derivatives |
| US6266453B1 (en) | 1999-07-26 | 2001-07-24 | Computerized Medical Systems, Inc. | Automated image fusion/alignment system and method |
| ES2258431T3 (es) * | 1999-08-02 | 2006-09-01 | F. Hoffmann-La Roche Ag | Proceso para la preparacion de derivados de benzotiofeno. |
| WO2001012189A1 (en) * | 1999-08-12 | 2001-02-22 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| SE9904044D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
| US6906072B1 (en) * | 2000-01-20 | 2005-06-14 | Eisai Co., Ltd. | Piperazine compound and pharmaceutical composition containing the compound |
| US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US20020065219A1 (en) * | 2000-08-15 | 2002-05-30 | Naidu B. Narasimhulu | Water soluble thiazolyl peptide derivatives |
| US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
| EP1191024A1 (en) | 2000-09-22 | 2002-03-27 | Harald Tschesche | Thiadiazines and their use as inhibitors of metalloproteinases |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| KR20030082990A (ko) * | 2001-03-15 | 2003-10-23 | 아스트라제네카 아베 | 메탈로프로테이나제 억제제 |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| CA2447475A1 (en) * | 2001-05-25 | 2002-12-05 | Chu-Biao Xue | Hydantion derivatives as inhibitors of matrix metalloproteinases |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| CA2486350A1 (en) | 2002-06-05 | 2003-12-24 | Kaneka Corporation | Process for producing optically active .alpha.-methylcysteine derivative |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| SE0202693D0 (sv) * | 2002-09-11 | 2002-09-11 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| US7041693B2 (en) * | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| US20040266832A1 (en) * | 2003-06-26 | 2004-12-30 | Li Zheng J. | Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine |
| TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
| SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
| US7648992B2 (en) * | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| TW200740769A (en) * | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
-
2004
- 2004-12-17 SE SE0403085A patent/SE0403085D0/sv unknown
-
2005
- 2005-12-14 JP JP2007546609A patent/JP2008524210A/ja active Pending
- 2005-12-14 BR BRPI0517035-4A patent/BRPI0517035A/pt not_active IP Right Cessation
- 2005-12-14 RU RU2007126746/04A patent/RU2376301C2/ru not_active IP Right Cessation
- 2005-12-14 UA UAA200706657A patent/UA90285C2/ru unknown
- 2005-12-14 MX MX2007007023A patent/MX2007007023A/es active IP Right Grant
- 2005-12-14 ES ES05815745T patent/ES2380670T3/es not_active Expired - Lifetime
- 2005-12-14 EP EP05815745A patent/EP1831199B1/en not_active Expired - Lifetime
- 2005-12-14 WO PCT/SE2005/001917 patent/WO2006065215A1/en not_active Ceased
- 2005-12-14 NZ NZ555831A patent/NZ555831A/en not_active IP Right Cessation
- 2005-12-14 CA CA002590845A patent/CA2590845A1/en not_active Abandoned
- 2005-12-14 AU AU2005317286A patent/AU2005317286B2/en not_active Ceased
- 2005-12-14 US US11/721,586 patent/US7655664B2/en not_active Expired - Fee Related
- 2005-12-14 CN CNA2005800481778A patent/CN101119987A/zh active Pending
- 2005-12-14 AT AT05815745T patent/ATE545642T1/de active
- 2005-12-14 KR KR1020077013489A patent/KR20070090924A/ko not_active Ceased
- 2005-12-15 AR ARP050105273A patent/AR051795A1/es not_active Application Discontinuation
- 2005-12-15 MY MYPI20055915A patent/MY147770A/en unknown
- 2005-12-16 TW TW094144602A patent/TW200635917A/zh unknown
- 2005-12-17 SA SA05260409A patent/SA05260409B1/ar unknown
-
2007
- 2007-05-31 IL IL183599A patent/IL183599A/en not_active IP Right Cessation
- 2007-06-12 ZA ZA200705075A patent/ZA200705075B/xx unknown
- 2007-07-10 NO NO20073572A patent/NO20073572L/no not_active Application Discontinuation
-
2010
- 2010-02-01 US US12/697,625 patent/US20100256166A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10435389B2 (en) | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 | |
| JP2008524210A5 (https=) | ||
| TWI376374B (en) | Novel coumarin derivatives with antitumor activity | |
| JP2008505171A5 (https=) | ||
| JP5008778B2 (ja) | 新規５−フルオロウラシル誘導体 | |
| JP6990196B2 (ja) | ピリミジン誘導体 | |
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| CZ20024223A3 (cs) | Deriváty 4-chinazolinaminů, způsob výroby a farmaceutický prostředek | |
| JP2013526494A5 (https=) | ||
| JP6896701B2 (ja) | イミダゾリルアミド誘導体 | |
| JP2013032293A (ja) | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 | |
| TW201936585A (zh) | 5-氟尿嘧啶化合物 | |
| JP5524847B2 (ja) | Ｃｒｔｈ２アンタゴニストとしてのアルキルチオピリミジン | |
| RU2009133846A (ru) | Новые производные гидантоина в качестве ингибиторов металлопротеиназ | |
| RU2007126746A (ru) | Новые производные гидантоина в качестве ингибиторов металлопротеиназ | |
| JP6978003B2 (ja) | 複素環式化合物およびその使用 | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2008524211A5 (https=) | ||
| JP2001072660A (ja) | ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤 | |
| KR20180100225A (ko) | 7H-피롤로[2,3-d]피리미딘 화합물을 제조하기 위한 방법 | |
| EP1740550A1 (en) | Sulphur-linked imidazole compounds for the treament of hiv | |
| EP3640243A1 (en) | Piperazine derivatives for the treatment of hypertension and/or fibrosis | |
| CN102344444B (zh) | 光学纯喹唑啉类化合物 | |
| JP2008526828A (ja) | 逆転写酵素モジュレーターとしてのイミダゾール誘導体 | |
| TWI532736B (zh) | 光學純喹唑啉類化合物 |